Tim Hunt, CEO of the Alliance for Regenerative Medicine, contends that CGT companies are emerging stronger in 2026 from “hard lessons” learned after years of volatility.
The acquisition of the Tempe, Arizona facility will expand U.S.-based drug delivery device capacity and support the company’s $10 billion manufacturing investment.
The new Leiden-based facility will serve as European headquarters and support regional cell therapy manufacturing as programs move toward commercial supply.
